A multi-peptide COVID-19 vaccine, CoVac-1, has shown promising T-cell response and safety for patients with cancer who have disease- or treatment-related immunoglobulin deficiency, according to a phase 1/2 trial that was presented during American ...
from Google Alert - health https://ift.tt/Sba3s7u
via IFTTT
0 comments:
Post a Comment